65,437 trials
Stage II Prostate Adenocarcinoma · Stage III Prostate Adenocarcinoma
Primary: 68Ga-PSMA-11 PET Detection of Prostate Cancer Metastasized to Lymph Nodes — 19 Participants
Hypertriglyceridemia
Primary: Percent Change in Plasma Triglycerides (Pharmacodynamic Population) — -20.9; -18.3 Percent Change from baseline
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
Family Caregiving · Complex Care · Self Efficacy
Primary: Change in Caregiver Competency — 1.0; 1.0 score on a scale
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 — 1.2; 90.8 percentage of participants — p=<0.001
Stroke · Brain Diseases · Central Nervous System Diseases
Primary: A Change in the Fugl-Meyer Upper Extremity Assessment Score — 11; 12; 13; 14 units on a scale
Lung Transplant Infection
Primary: Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction — 2; 4 Participants
Peritoneal Dialysis-associated Peritonitis
Primary: Maximum Total Plasma Concentration (Cmax) — 28.7 mg/L
Heart Failure, Diastolic
Primary: Change in Health Status of Patients With HFpEF — 4.15; 26.56; 29.97; 33 Scores on a scale
Hypertension
Primary: Adverse Events — 1; 1; 1; 1 participants
Palmoplantar Pustulosis
Primary: Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline — 0.86; 0.53 Log transformed ratio — p=0.24
Osteoarthritis
Primary: Level of Physical Activity/Sedentary Time — 562; 572; 556; 556 minutes — p=<0.05
Depression, Unipolar · Mental Health Disorder
Primary: Change in Clinically Significant Depressive Symptoms (MADRS) — 21.21; 21; 18.5; 15.77 score on a scale — p=0.31
Alzheimer Disease
Primary: Change in Amyloid Burden — -1.55 dSUVR
Orthopedic Disorder
Primary: Total Time to Perform the Regional Anesthesia Technique — 3; 6 minutes